Micot reports MT200605 findings in Huntington’s disease and stroke
Shaanxi Micot presented preclinical and Phase I results for MT200605 and cited earlier positive Phase II findings in acute ischemic stroke.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Shaanxi Micot Pharmaceutical Technology Co., Ltd. presented nonclinical results and Phase I data from healthy volunteers for MT200605 at MDS 2026. The company also referred to previously disclosed positive Phase II findings in acute ischemic stroke: the high-dose group showed a significant benefit, while an exploratory analysis found acute kidney injury incidence was more than 80% below the placebo rate.
In Huntington’s disease mouse studies, the compound improved motor measures and reduced atrophy. The Phase I study produced mild adverse events and predictable pharmacokinetics. TradingView said its item was based on a company press release distributed by Asian Corporate Newswire and warned that the AI-generated summary may contain inaccuracies.
why it matters
The update adds early-stage evidence to previously reported Phase II signals in stroke. Further studies and confirmation of the findings will be needed to assess the drug’s prospects; this is not investment advice.
sources
- Shaanxi Micot Pharmaceutical Technology Co., Ltd. Shares HD Preclinical, Phase I Data; Stroke Ph2 Positive — TradingView, 12 October 2026 at 08:52 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗